XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
Phase 1
Recruiting
- Conditions
- ObesityType 2 Diabetes Mellitus
- Interventions
- Drug: Oral ecnoglutide tabletDrug: T2026Drug: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05184322
- Locations
- 🇦🇺
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane), Herston, Queensland, Australia
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT05111912
- Locations
- 🇦🇺
Paratus Clinical Research Brisbane, Brisbane, Queensland, Australia
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
Phase 2
Withdrawn
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome
- Interventions
- Drug: XW001Drug: Placebo
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
- Registration Number
- NCT05083117
- Locations
- 🇦🇷
Hospital Pirovano, Caba, Bs AS, Argentina
🇵🇪Hospital Nacional Arzobispo Loayza, Lima, Peru
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusNonalcoholic SteatohepatitisObesity
- Interventions
- Drug: Cohort ADrug: Placebo ADrug: Cohort BDrug: Placebo B
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04389775
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath